We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study.
- Authors
Margarit, César; Roca, Reyes; Inda, María‐del‐Mar; Muriel, Javier; Ballester, Pura; Moreu, Rocío; Conte, Anna Lucia; Nuñez, Angela; Morales, Domingo; Peiró, Ana M
- Abstract
Objectives: Chronic pain is one of the most common reasons individuals seek medical attention. It is a major issue because of the wide interindividual variability in the analgesic response. This might be partly explained by the presence of variants in genes encoding molecules involved in pharmacodynamics and pharmacokinetics. The aim was to analyze opioid effectiveness in chronic low back pain (CLBP) relief after opioid titration, unveiling the impact of pharmacogenetics. Methods: The study included 231 opioid‐naïve patients from the Spine Unit; age 63 ± 14 years, 64% female, body mass index 29 ± 6 kg/m2, visual analog scale pain intensity score 73 ± 16 mm. Clinical data were collected at baseline, 3 months after opioid titration, and after 2 to 4 years of follow‐up concerning pain (intensity and relief), quality of life, disability, comorbidities, and drug prescription (opioid dose, rotations, and adverse events). The genotype influence of OPRM1,COMT,UGT2B7,ABCB1,KCNJ6, and CYP3A5*3A in analgesic response was analyzed by reverse‐transcription polymerase chain reaction genotyping. Results: Patients with the COMT G472A‐AA genotype (rs4680) and KCNJ6 A1032G‐A allele (rs2070995) CLBP responded differently to opioid titration, with higher pain intensity requiring higher dosing. Furthermore, GG‐ genotypes of A118G (OPRM1, rs1799971) and A854G (UGT2B7, rs776746) influenced the neuropathic component. After opioid titration, CLBP intensity, neuropathic component, low back pain disability, anxiety, and depression significantly decreased, while quality of life improved. Conclusion: Single‐nucleotide polymorphisms in genes involved in pain transmission and opioid metabolism might predispose to exaggerated sensitivity and differences in the opioid analgesic effect in patients with CLBP. We encourage clinical trials for their clinical application in chronic pain management.
- Subjects
ANXIETY prevention; PREVENTION of mental depression; THERAPEUTIC use of narcotics; ANALGESICS; CHRONIC pain; GENETIC polymorphisms; LONGITUDINAL method; MEDICAL prescriptions; NARCOTICS; PHARMACOGENOMICS; POLYMERASE chain reaction; QUALITY of life; COMORBIDITY; PAIN measurement; BODY mass index; VISUAL analog scale; TREATMENT effectiveness; REVERSE transcriptase polymerase chain reaction; GENOTYPES; LUMBAR pain
- Publication
Pain Practice, 2019, Vol 19, Issue 8, p836
- ISSN
1530-7085
- Publication type
Article
- DOI
10.1111/papr.12816